CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 58 enrolled
Drug / intervention
RP6530drug
Likely dose
RP6530 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02567656
NCT02567656Phase 1Completed
CompareCT.gov

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma

Rhizen Pharmaceuticals SA·interventional·Posted Oct 5, 2015·Updated Jan 13, 2020

In Brief

A Phase 1 clinical trial evaluating RP6530 for Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous. Completed, enrolled 58 participants across 8 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 5, 2015
Enrollment StartSep 1, 2015
Primary CompletionMar 1, 2018
Study CompletionDec 10, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.7 years ago

Interventions

RP6530drug

Tablet starting at 200 mg